Network origin in Loren Aguiar first degree
Entity | Entity type | Industry | |
---|---|---|---|
Subsidiary | Pharmaceuticals: Major | 21 | |
Public Company | Pharmaceuticals: Major | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Loren Aguiar via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Comptroller/Controller/Auditor Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
NXERA PHARMA CO., LTD. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Undergraduate Degree | |
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal | |
AKILI, INC. | Medical Specialties | Director/Board Member Director/Board Member | |
AMARIN CORPORATION PLC | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
University of Connecticut | College/University | Undergraduate Degree Graduate Degree | |
K36 Therapeutics, Inc.
K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | Pharmaceuticals: Major | Director/Board Member | |
University of Glasgow | College/University | Doctorate Degree | |
Prometheus Laboratories, Inc.
Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | Biotechnology | Corporate Officer/Principal | |
Pfizer Europe International Ltd.
Pfizer Europe International Ltd. Pharmaceuticals: MajorHealth Technology Pfizer Europe International Ltd. is an Irish company. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Pfizer Japan, Inc.
Pfizer Japan, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Pfizer Japan, Inc. is a research and Japanese development pharmaceutical company founded in 1953. The company is based in Tokyo, Japan. The company's focus is on breakthroughs that greatly change patients' lives, contributing to the improvement of patients' health and life expectancy. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
PORTAGE BIOTECH INC. | Biotechnology | Chief Executive Officer | |
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | Pharmaceuticals: Major | Sales & Marketing | |
Portage Pharma Ltd.
Portage Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Portage Pharma Ltd. develops pharmaceutical products. The There is no available country named vg company was founded by Declan Doogan, Gregory H. Bailey. Bruce H. Littman has been the CEO of the company since 2013. Portage Pharma was acquired by Portage Biotech, Inc. on June 04, 2013 for $34.84 million. | Pharmaceuticals: Major | Founder | |
The Pulmonary Vascular Research Institute
The Pulmonary Vascular Research Institute Miscellaneous Commercial ServicesCommercial Services The Pulmonary Vascular Research Institute operates as a medical research charity. The non-profit company is based in Canterbury, UK. | Miscellaneous Commercial Services | Director/Board Member | |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | Pharmaceuticals: Major | Founder | |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
INTENSITY THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | Pharmaceuticals: Major | Director/Board Member | |
iOX Therapeutics Ltd.
iOX Therapeutics Ltd. BiotechnologyHealth Technology iOX Therapeutics Ltd. provides cancer therapeutics services. The company was founded by Vincenzo Cerundolo in February 2015 and is headquartered in London, the United Kingdom. | Biotechnology | Chairman | |
Kleo Pharmaceuticals, Inc.
Kleo Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kleo Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of biospecific compounds designed to emulate and enhance the activity of biologics. Its compounds are designed to direct the immune system to destroy cancerous or virally infected cells, and treatment of multiple myeloma and COVID-19. It offers Antibody Recruiting Molecules (ARMs),Synthetic Antibody Mimics (SyAMs), and Monoclonal Antibody Therapy Enhancers (MATEs) pipeline. The company was founded by David A. Spiegel and Roy Prieb in 2015 and is headquartered in New Haven, CT. | Miscellaneous Commercial Services | Director/Board Member | |
Juvenescence Ltd.
Juvenescence Ltd. Financial ConglomeratesFinance Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom. | Financial Conglomerates | Founder | |
Harvard T.H. Chan School of Public Health | College/University | Corporate Officer/Principal | |
Kitasato University | College/University | Corporate Officer/Principal | |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Chairman | |
Indalo Therapeutics, Inc.
Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | Biotechnology | Chairman | |
SYNLOGIC, INC. | Biotechnology | Director/Board Member | |
Philadelphia Ventures, Inc.
Philadelphia Ventures, Inc. Investment ManagersFinance Philadelphia Ventures Inc (Philadelphia Ventures) was a venture capital firm founded in 1967 by Norley Michael. The firm was headquartered in Philadelphia, Pennsylvania. | Investment Managers | Corporate Officer/Principal | |
3-Dimensional Pharmaceuticals, Inc.
3-Dimensional Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology 3-Dimensional Pharmaceuticals, Inc. was acquired by Johnson & Johnson. 3-Dimensional Pharmaceuticals, Inc. operates as a drug discovery and development company that has a pipeline of drug candidates in the areas of cancer and inflammation, and metabolic and cardiovascular diseases | Pharmaceuticals: Major | Director/Board Member | |
EIDOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
BRIDGEBIO PHARMA, INC. | Biotechnology | Director/Board Member | |
BIOMEA FUSION, INC. | Pharmaceuticals: Major | Director/Board Member | |
Garuda Therapeutics, Inc.
Garuda Therapeutics, Inc. BiotechnologyHealth Technology Garuda Therapeutics, Inc. aims to eliminate the need for donor or patient cells for blood stem cell transplants. The company is based in Natick, MA. The company's platform technology generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free. This technology could potentially provide curative therapies for over 120 diseases. Garuda Therapeutics was founded by Dhvanit Shah, Sean Morrison, and David T. Scadden, with Dhvanit Shah serving as CEO since incorporation. | Biotechnology | Director/Board Member | |
COLLEGIUM PHARMACEUTICAL, INC. | Pharmaceuticals: Major | Founder | |
TYRX, Inc.
TYRX, Inc. Electronic Equipment/InstrumentsElectronic Technology TYRX, Inc. designs and manufactures medical-pharmaceutical combination devices. The firm commercializes implantable combination drug and device products focused on infection control including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs). Its AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including superbugs such as methicillin-resistant S. aureus (MRSA). The company was founded in 1998 by Satish Pulapura and Arikha Moses and is headquartered in Monmouth Junction, NJ. | Electronic Equipment/Instruments | Director/Board Member | |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Biotechnology | Chairman | |
ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
CORNERSTONE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
OCATA THERAPEUTICS INC | Pharmaceuticals: Major | Chairman | |
Onset Dermatologics LLC
Onset Dermatologics LLC Pharmaceuticals: MajorHealth Technology Onset Dermatologics LLC develops and markets prescription product for skin disorders. The company was founded in 2005 and is headquartered in Cumberland, RI. | Pharmaceuticals: Major | Chief Executive Officer |
Statistics
International
United States | 36 |
United Kingdom | 7 |
Japan | 4 |
Ireland | 3 |
Australia | 2 |
Sectoral
Health Technology | 38 |
Consumer Services | 6 |
Commercial Services | 5 |
Finance | 3 |
Electronic Technology | 2 |
Operational
Director/Board Member | 126 |
Corporate Officer/Principal | 50 |
Independent Dir/Board Member | 41 |
Chairman | 25 |
Undergraduate Degree | 17 |
Most connected contacts
Insiders | |
---|---|
Albert Cha | 30 |
Eric Aguiar | 29 |
Declan Doogan | 28 |
Robert Hugin | 24 |
Michael Heffernan | 23 |
Julia Gregory | 22 |
Kishan Mehta | 15 |
William Jones | 14 |
Matthew Buten | 13 |
Robert Repella | 10 |
Clifford Bechtold | 6 |
Megan M. Dow | 6 |
James Engelhart | 6 |
Jennifer Porcelli | 5 |
Scott Phillips | 4 |
- Stock Market
- Insiders
- Loren Aguiar
- Company connections